Oncolytics Biotech Inc
TSX:ONC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Terveystalo Oyj
OMXH:TTALO
|
FI |
|
CIE Automotive India Ltd
NSE:CIEINDIA
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (0.2), the stock would be worth CA$-0.59 (104% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.2 | CA$14.9 |
0%
|
| 3-Year Average | 0.2 | CA$-0.59 |
-104%
|
| 5-Year Average | 0.3 | CA$-0.8 |
-105%
|
| Industry Average | 12.3 | CA$-35.4 |
-338%
|
| Country Average | 10.2 | CA$-29.39 |
-297%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Oncolytics Biotech Inc
TSX:ONC
|
173.1m CAD | -5.2 | -5.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 14.3 | 86.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 12.2 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 21.2 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 41.4 | 38.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 10.5 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Oncolytics Biotech Inc
Glance View
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
